MEDA Pharma GmbH

Company snapshot

MEDA Pharma GmbH is a pharma organization headquartered in CN. Primary therapeutic focus areas include Syphilis, Human Immunodeficiency Virus, Non Alcoholic Fatty Liver Disease, Human immunodeficency virus, COVID-10 infection. NovaPharmaNews links 8 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 2 (5), approved (2).

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for MEDA Pharma GmbH. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for MEDA Pharma GmbH.

1. Jun 8, 2026 Clinical update

   BCN05-Bari — Phase 2

2. Jun 8, 2026 Clinical update

   DORALI — Approved

3. Jun 8, 2026 Clinical update

   THALASSA 2.0 — Phase 2

4. Jun 8, 2026 Clinical update

   Empagliflozin — Unknown

5. Jun 8, 2026 Clinical update

   BENZATHINE BENZYLPENICILLIN , LINEZOLID — Approved

View all clinical trial activity →

• What is MEDA Pharma GmbH?

  MEDA Pharma GmbH is a pharma organization headquartered in CN. Primary therapeutic focus areas include Syphilis, Human Immunodeficiency Virus, Non Alcoholic Fatty Liver Disease, Human immunodeficency virus, COVID-10 infection. NovaPharmaNews links 8 clinical program(s), 0 drug pr

• Is MEDA Pharma GmbH publicly traded?

  MEDA Pharma GmbH appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does MEDA Pharma GmbH develop or market?

  We link 28 drug profile(s) where MEDA Pharma GmbH is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/meda-ab#company-drugs.

• What are the latest developments for MEDA Pharma GmbH?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does MEDA Pharma GmbH focus on?

  MEDA Pharma GmbH focuses on Syphilis, Human Immunodeficiency Virus, Non Alcoholic Fatty Liver Disease based on our analysis of their pipeline programs and drug development activities.